Post by Bristol Myers Squibb on X
Bristol Myers Squibb@bmsnews
XToday, we announced a global strategic partnership with @BioNTech_Group to co-develop and co-commercialize BNT327, an investigational, next-generation PD-L1/VEGF bispecific antibody, across numerous solid tumor types. Learn more: t.co

46 likes2 repliesPosted Jun 2, 2025